PF-05221304
Phase 1Completed 0 watching 0 views this week💤 Quiet
32
Development Stage
✓
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Normal Healthy
Conditions
Normal Healthy
Trial Timeline
Aug 1, 2016 → Mar 1, 2017
NCT ID
NCT02871037About PF-05221304
PF-05221304 is a phase 1 stage product being developed by Pfizer for Normal Healthy. The current trial status is completed. This product is registered under clinical trial identifier NCT02871037. Target conditions include Normal Healthy.
Hype Score Breakdown
Clinical
10
Activity
5
Company
9
Novelty
3
Community
2
Clinical Trials (2)
| NCT ID | Phase | Status |
|---|---|---|
| NCT03309202 | Phase 1 | Completed |
| NCT02871037 | Phase 1 | Completed |
Competing Products
20 competing products in Normal Healthy
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| Roxadustat | Astellas Pharma | Phase 1 | 33 |
| Donepezil | Eisai | Approved | 85 |
| eribulin mesylate | Eisai | Phase 2 | 52 |
| Lurasidone HCl | Sumitomo Pharma | Phase 1 | 33 |
| Eybelis ophthalmic solution 0.002% | Santen Pharmaceutical | Approved | 85 |
| Triptorelin | Merck | Pre-clinical | 23 |
| Temozolomide + Vorinostat | Merck | Phase 2 | 52 |
| LDE225 | Novartis | Phase 1 | 33 |
| LDK378 | Novartis | Phase 1 | 33 |
| cyclosporine micro-emulsion | Novartis | Approved | 85 |
| LDK378 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| LEE011 | Novartis | Phase 1 | 33 |
| mycophenolate mofetil | Roche | Phase 1 | 33 |
| filgrastim | Amgen | Pre-clinical | 22 |
| PF-06423264 | Pfizer | Phase 1 | 32 |
| BMS-933043 + Placebo matching with BMS-933043 + Antacid Buffer Predose Solution | Bristol Myers Squibb | Phase 1 | 32 |
| tolebrutinib | Sanofi | Phase 1 | 32 |
| Venglustat (GZ402671) | Sanofi | Phase 1 | 32 |
| Rilzabrutinib | Sanofi | Phase 1 | 32 |